NASDAQ:TCON TRACON Pharmaceuticals (TCON) Stock Price, News & Analysis $0.71 -0.24 (-25.47%) (As of 09:46 AM ET) Add Compare Share Share Today's Range$0.71▼$0.7150-Day Range$0.85▼$2.0252-Week Range$0.66▼$14.75Volume4,405 shsAverage Volume188,802 shsMarket Capitalization$2.36 millionP/E Ratio1.06Dividend YieldN/APrice Target$60.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends Get TRACON Pharmaceuticals alerts: Email Address TRACON Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside6,215.8% Upside$60.00 Price TargetShort InterestBearish6.64% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.38Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.82) to ($0.19) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.54 out of 5 stars 3.2 Analyst's Opinion Consensus RatingTRACON Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageTRACON Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about TRACON Pharmaceuticals' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.64% of the float of TRACON Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverTRACON Pharmaceuticals has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in TRACON Pharmaceuticals has recently increased by 39.58%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldTRACON Pharmaceuticals does not currently pay a dividend.Dividend GrowthTRACON Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TCON. Previous Next 1.5 News and Social Media Coverage News SentimentTRACON Pharmaceuticals has a news sentiment score of -0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for TRACON Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 7 people have searched for TCON on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows6 people have added TRACON Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, TRACON Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.27% of the stock of TRACON Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 11.61% of the stock of TRACON Pharmaceuticals is held by institutions.Read more about TRACON Pharmaceuticals' insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for TRACON Pharmaceuticals are expected to grow in the coming year, from ($2.82) to ($0.19) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TRACON Pharmaceuticals is 1.42, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 126.14.Price to Earnings Ratio vs. SectorThe P/E ratio of TRACON Pharmaceuticals is 1.42, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 103.77.Read more about TRACON Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.In answer to this issue, we have released a Special Report to the public. About TRACON Pharmaceuticals Stock (NASDAQ:TCON)TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. In addition, it is developing bispecific antibodies, which are in preclinical stage. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309 and bispecific antibodies; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.Read More TCON Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TCON Stock News HeadlinesJuly 4, 2024 | americanbankingnews.comHC Wainwright Equities Analysts Cut Earnings Estimates for TRACON Pharmaceuticals, Inc. (NASDAQ:TCON)July 3, 2024 | americanbankingnews.comTRACON Pharmaceuticals (NASDAQ:TCON) Given "Neutral" Rating at HC WainwrightJuly 8, 2024 | Theo Trade (Ad)Replace Lost Dividend Income with This…Introducing Ultima Trades, a unique strategy designed by Don Kaufman. Ultima Trades capitalize on market inflection points to deliver substantial returns, providing a powerful alternative to traditional dividends. Imagine securing gains like 21%, 30%, or even 305% in just hours or days, ensuring a reliable source of income.July 1, 2024 | americanbankingnews.comTRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Short Interest Up 39.6% in JuneJune 29, 2024 | americanbankingnews.comStockNews.com Downgrades TRACON Pharmaceuticals (NASDAQ:TCON) to HoldJune 11, 2024 | globenewswire.comTRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma PatientsMay 15, 2024 | msn.comTRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q1 2024 Earnings Call TranscriptMay 15, 2024 | finance.yahoo.comQ1 2024 TRACON Pharmaceuticals Inc Earnings CallJuly 8, 2024 | Theo Trade (Ad)Replace Lost Dividend Income with This…Introducing Ultima Trades, a unique strategy designed by Don Kaufman. Ultima Trades capitalize on market inflection points to deliver substantial returns, providing a powerful alternative to traditional dividends. Imagine securing gains like 21%, 30%, or even 305% in just hours or days, ensuring a reliable source of income.May 15, 2024 | finance.yahoo.comTRACON Pharmaceuticals Inc (TCON) Q1 2024 Earnings Call Transcript Highlights: Strategic ...May 14, 2024 | investorplace.comTCON Stock Earnings: TRACON Pharma Misses EPS for Q1 2024May 14, 2024 | finance.yahoo.comTRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 14, 2024 | globenewswire.comTRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 7, 2024 | globenewswire.comTRACON to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024April 26, 2024 | money.usnews.comTRACON Pharmaceuticals IncApril 10, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for TRACON Pharmaceuticals Post-Reverse Split and Envafolimab Valuation UpdateApril 10, 2024 | uk.investing.comTRACON announces 1-for-20 reverse stock splitApril 10, 2024 | investorplace.comWall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for April 2024See More Headlines Receive TCON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TRACON Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Ex-Dividend for 7/8 Dividend6/27/2024Today7/08/2024Dividend Payable7/08/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:TCON CUSIPN/A CIK1394319 Webwww.traconpharma.com Phone(858) 550-0780Fax858-550-0786Employees17Year FoundedN/APrice Target and Rating Average Stock Price Target$60.00 High Stock Price Target$60.00 Low Stock Price Target$60.00 Potential Upside/Downside+6,215.8%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)$0.67 Trailing P/E Ratio1.42 Forward P/E RatioN/A P/E GrowthN/ANet Income$-3,590,000.00 Net MarginsN/A Pretax Margin13.98% Return on Equity-114.48% Return on Assets59.65% Debt Debt-to-Equity RatioN/A Current Ratio0.80 Quick Ratio0.80 Sales & Book Value Annual Sales$12.05 million Price / Sales0.26 Cash Flow$1.70 per share Price / Cash Flow0.56 Book Value($0.37) per share Price / Book-2.57Miscellaneous Outstanding Shares3,330,000Free Float2,538,000Market Cap$3.16 million OptionableNo Data Beta1.28 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Charles P. Theuer M.D. (Age 60)Ph.D., Chairman, CEO & President Comp: $646.6kMr. Scott B. Brown CPA (Age 43)M.S., Chief Financial Officer Comp: $403.1kDr. James L. Freddo M.D. (Age 69)Chief Medical Officer Mr. Ya HuangExecutive Director of Statistical ProgrammingKey CompetitorsOrganovoNASDAQ:ONVOCoeptis TherapeuticsNASDAQ:COEPInhibikase TherapeuticsNYSE:IKTChromocell TherapeuticsNYSE:CHROGenetic TechnologiesNASDAQ:GENEView All Competitors TCON Stock Analysis - Frequently Asked Questions How have TCON shares performed this year? TRACON Pharmaceuticals' stock was trading at $3.5020 on January 1st, 2024. Since then, TCON stock has decreased by 72.9% and is now trading at $0.95. View the best growth stocks for 2024 here. How were TRACON Pharmaceuticals' earnings last quarter? TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) announced its quarterly earnings results on Tuesday, May, 14th. The biopharmaceutical company reported ($1.33) earnings per share for the quarter, missing analysts' consensus estimates of ($1.20) by $0.13. The biopharmaceutical company had revenue of $0.10 million for the quarter. When did TRACON Pharmaceuticals' stock split? TRACON Pharmaceuticals shares reverse split on Wednesday, April 10th 2024. The 1-20 reverse split was announced on Wednesday, April 10th 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 10th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did TRACON Pharmaceuticals IPO? TRACON Pharmaceuticals (TCON) raised $47 million in an initial public offering (IPO) on Friday, January 30th 2015. The company issued 3,600,000 shares at a price of $12.00-$14.00 per share. Wells Fargo Securities and Stifel acted as the underwriters for the IPO and Needham & Company and Oppenheimer were co-managers. How do I buy shares of TRACON Pharmaceuticals? Shares of TCON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of TRACON Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that TRACON Pharmaceuticals investors own include NVIDIA (NVDA), OPKO Health (OPK), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Verastem (VSTM), Inovio Pharmaceuticals (INO) and T2 Biosystems (TTOO). This page (NASDAQ:TCON) was last updated on 7/8/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored50-year Wall Street Legend: “Prepare for a cash avalanche”The Dow crossed 40,000 for the first time in history… The S&P has hit over 30 all-time highs since the star...Chaikin Analytics | SponsoredObama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happ...Porter & Company | SponsoredTrump’s Gift Could Unleash $51 Billion in New WealthIn January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house...Wealthpin Pro | SponsoredNew Government Policy to Wipe Out Seniors WealthDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | SponsoredNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Weiss Ratings | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TRACON Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TRACON Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
